Direct Thrombin Inhibitor international drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,992,514	⤷ Start Trial	Y			⤷ Start Trial
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,903,993	⤷ Start Trial				⤷ Start Trial
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	12,472,224	⤷ Start Trial	Y			⤷ Start Trial
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,918,622	⤷ Start Trial				⤷ Start Trial
Caplin	ARGATROBAN	argatroban	INJECTABLE;INJECTION	214235-001	Jan 21, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Gland	ARGATROBAN	argatroban	INJECTABLE;INJECTION	217848-001	Jul 31, 2023	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 15, 2026

Direct thrombin inhibitors (DTIs) span anticoagulation across atrial fibrillation (AF), venous thromboembolism (VTE), acute coronary syndromes (ACS), percutaneous coronary intervention (PCI), and HIT. Patent estates and FDA exclusivity historically favored a small set of brands: dabigatran etexilate (oral), bivalirudin (invasive setting), argatroban (HIT), and the development pipeline around reversible ATP-site and substrate-site DTIs. As key oral exclusivities roll off, market share is driven by: (1) the competitive position vs factor Xa inhibitors (FXaIs), (2) reversal and bleeding profile perceptions, (3) uptake in hospital formularies, and (4) procedural-use switching (PCI/ACS).

This report maps the DTI competitive landscape and the most decision-relevant patent risk: Orange Book exclusivity status, likely generic entry windows, formulation and method-of-use patent coverage, biosimilar-like analog risk (where relevant), and litigation patterns typical for anticoagulants.

Which direct thrombin inhibitor drugs dominate the market today and why?

Featured answer: Market dominance concentrates in dabigatran (oral anticoagulation) and bivalirudin (procedural anticoagulation), with argatroban a smaller, acute-care niche in HIT.

Core commercial segments for DTIs

Chronic anticoagulation (nonvalvular AF, stroke prevention): Dabigatran etexilate is the main DTI incumbent.
Hospital/ICU and procedural anticoagulation: Bivalirudin is the principal DTI used during catheter-based interventions (PCI) and certain ACS pathways.
HIT and thrombocytopenia contexts: Argatroban is the main DTI used where heparin exposure is contraindicated (or for alternative anticoagulation protocols).

How DTI brands compete versus FXa inhibitors

Clinical guideline positioning: FXaIs generally gained broad uptake for AF and VTE because of dosing simplicity and predictable use. DTIs retained roles based on physician familiarity and bleeding/reversal considerations where applicable.
Formulary inertia and procurement: Hospital purchasing often favors one or two INR-independent agents for anticoagulation pathways, which can reduce switching unless outcome data or cost changes justify change.
Reversal and operational readiness: Dabigatran is historically associated with a specific reversal option (idarucizumab) which can affect formulary selection, especially for higher-risk bleeding settings.

What patents protect dabigatran etexilate (Pradaxa) in the US and what are the key expiration drivers?

Featured answer: Dabigatran’s US patent estate historically covered: (1) active ingredient and salt form, (2) prodrug formulation (etexilate), (3) manufacturing processes, and (4) method-of-use for anticoagulation indications. Many core protections have expired, with remaining value often in formulation/process and any later-life improvements.

Patent estate structure typically seen for dabigatran

API and prodrug chemistry: Salt/prodrug claims around dabigatran etexilate.
Solid-state and formulation: Tablet composition, dissolution behavior, excipient systems.
Manufacturing method: Processes controlling granulation, milling, and conversion steps.
Use claims: AF, VTE treatment, and extended prophylaxis methods tied to specific dosing regimens.

Timing mechanics that drive generic risk

For small-molecule oral anticoagulants, exclusivity and patents expire on a predictable ladder:

Composition-of-matter: usually the last major gate for generic entry.
Method-of-use: can delay label copying or force carve-outs even after composition expiry.
Formulation/process: can produce “late” barriers if they are still in force at the intended filing date.

When does dabigatran lose exclusivity and what generic entry risks remain?

Featured answer: Generic competition for dabigatran started after the major composition and prodrug protections expired; remaining risks typically concentrate on any still-active formulation or method-of-use patents, plus label restrictions.

Generic entry risk model

Scenario A: Full ANDA with Paragraph IV to any remaining Orange Book patents
- Lowest risk if no protected method claims overlap planned label.
Scenario B: Design-around formulation/process
- Higher cost and development time if the remaining patents cover dissolution, coating, or excipient systems.
Scenario C: Label carve-out due to method-of-use
- Commercial impact if the generic can’t market key AF/VTE claims on day one.

Market consequence

Even when composition patents are gone, remaining patents can:

Delay “paragraph IV to launch at-risk”
Force settlement with delayed approval dates
Constrain bioequivalence strategies tied to dissolution profiles

What is the Orange Book status of dabigatran and how many patents are listed?

Featured answer: Dabigatran’s Orange Book listing historically included multiple patent families across composition, formulation, and use. The number of listed patents varies by filing scope and prosecution lineage, with later additions tied to formulation/process and repackaging or related lifecycle activities.

How to interpret Orange Book listings for diligence

Expiration mapping: Use earliest expiring claims by patent number and patent term adjustment status.
Which patents matter for entry: Prioritize patents that correspond to the drug product (NDC-specific) and those with claim coverage aligned to bioavailability and label.

What patents protect bivalirudin (Angiomax) and what is the expiration and generic challenge timeline?

Featured answer: Bivalirudin’s protection historically concentrated on peptide manufacture, formulation, and method-of-use in PCI and ACS pathways. Because bivalirudin is used in hospital catheter procedures, manufacturing consistency and peptide-quality claims are commercially material even after label entry.

Bivalirudin patent estate: what tends to be covered

Peptide composition and sequence/derivative scope: Core DTIs and specific bivalirudin identity.
Manufacturing processes: In-process controls, purification, lyophilization or solution prep.
Formulation: Sterility, stability, aggregation control.
Use claims: Anticoagulation protocols in PCI/ACS.

Why generic risk differs vs oral DTIs

Quality-by-design scrutiny: Peptide/sterile injectables face high analytical burden. Patent coverage on manufacturing can delay supply even after composition expiry.
Hospital switching: Procurement contracts can lock-in supplier pricing and reliability, and switching costs can outweigh marginal drug price differences.

How do patent barriers for argatroban (Acova) compare with bivalirudin and dabigatran?

Featured answer: Argatroban’s estate is typically smaller and more niche, focused on formulation stability and therapeutic use. Commercially, argatroban is less exposed to broad outpatient generic substitution and more exposed to hospital protocol adherence.

Argatroban diligence focus

Sterile formulation patents: concentration, diluent systems, and stability.
Method-of-use coverage: HIT protocols and monitoring methods.
Manufacturing controls: impurity profiles and peptide or small-molecule synthetic control points (depending on the specific API manufacturing claims).

Market dynamic

Because argatroban use is protocol-driven, at-risk generic adoption is often limited unless hospital systems confirm equivalence, supply reliability, and compatibility with HIT pathways.

Which DTIs face the highest generic substitution pressure and where does patent risk concentrate?

Featured answer: Oral DTIs (especially dabigatran) face the highest generic substitution pressure. Injection DTIs (bivalirudin, argatroban) face less volume-driven pressure but higher manufacturing and formulation patent risk.

Risk concentration map by drug type

Oral DTIs: formulation dissolution and prodrug behavior; method-of-use and label scope.
Injectable DTIs: manufacturing process claims, sterility/stability, and product-quality patents.
Procedural-only DTIs: use and protocol claims tied to PCI/ACS pathways.

What patent litigation patterns affect DTIs in the US, including Paragraph IV challenges?

Featured answer: DTI litigation has followed the standard pattern for small-molecule brands: Paragraph IV challenges targeting remaining Orange Book-listed formulation/process/use patents. Settlements often trade early entry for later approval dates tied to the last expiring protected claims.

Typical DTI litigation outcomes

Early dismissals or non-infringement victories can occur if the challenger design avoids formulation/process claims.
Claim construction disputes often dominate because anticoagulant formulation patents use functional language tied to dissolution, stability, or release profiles.
Settlement agreements commonly set:
- A delayed approval date
- Carve-outs on labeling or manufacturing design
- Payment-for-delay economics (where permitted and disclosed)

What matters for business decisions

Identify which patents are actually litigated versus listed.
Track whether settlements include “at launch” carve-outs (often method-of-use related).
Measure how much of the label the generic can market once approved.

How does competition from factor Xa inhibitors change DTI market share and patent leverage?

Featured answer: FXaIs pressure DTI revenues and reduce the economic value of extending patent life. That increases the likelihood that life-cycle patent enforcement is focused on specific high-value subindications or formulations rather than broad claim sets.

Economic pressure points

List-price and rebate intensity: FXaIs generally drive aggressive pricing and contracting, particularly in large health systems.
Guideline drift: Even small preference shifts away from DTIs can reduce the returns from litigation and lifecycle strategies.
Therapeutic switching risk: With fewer distinct clinical advantages, DTIs are exposed when generic FXaIs reduce cost differentials.

What formulations are protected by DTI patents and do they block bioequivalent generic launches?

Featured answer: For oral DTIs, formulation patents can block generic launches through dissolution and release profile claim coverage, even if composition-of-matter is expired. For injectables, manufacturing and stability-related patents can delay approval or require process redesign.

Formulation claim types that commonly affect generic feasibility

Solid-state form: specific polymorph or controlled particle-size regimes.
Excipients and ratios: coatings and release modifiers tied to dissolution.
Process parameters: milling/granulation profiles controlling bioavailability.
Stability claims: impurity formation controls and acceptable degradation limits.

Bioequivalence as the bridge

Generic approval often depends on meeting dissolution and pharmacokinetic targets. If patents cover those performance characteristics by claim language, “design-around” can be costly even where generic bioequivalence is feasible.

Are DTIs subject to biosimilar-like risk, or are they purely small-molecule generic stories?

Featured answer: DTIs like dabigatran, bivalirudin, argatroban are chemical or peptide drugs, not biologics. The main risk is standard small-molecule generic substitution (ANDAs) or generic injectables, not biosimilars.

What to focus on instead of biosimilars

Process chemistry and peptide manufacturing controls
Sterile manufacturing validation and impurity profiles
Orange Book patent listings and litigation settlements

How do manufacturing/IP barriers delay DTI generic supply even after approvals?

Featured answer: For peptide/sterile DTI injectables and prodrug oral products, regulatory and quality barriers can be as material as patent barriers. Even “approved” generics can be delayed by manufacturing validation, analytical method transfer, and batch release issues tied to impurity specifications.

Operational barriers

Analytical method transfer
Impurity control and characterization
Stability under shipping and storage
Batch-to-batch consistency for peptides

Which companies are most exposed to DTI patent expiration, and who historically litigates or settles?

Featured answer: Exposure concentrates among branded incumbents with late-life formulation/use patents and generic filers pursuing Paragraph IV. The settlement ecosystem for anticoagulants typically includes large generic manufacturers and specialty generic firms.

Diligence targets

Branded holders: direct marketing rights plus manufacturing owners.
Generic challengers: companies that filed ANDAs with Paragraph IV notices.
Third-party litigation financiers or co-owners: when partnerships exist around formulation IP.

Key timelines: how DTI exclusivity lifecycles translate into market entry events

Featured answer: DTI brand value typically compresses at two points: (1) expiration of core composition/prodrug patents and (2) expiration or settlement-driven release of remaining formulation/use patents.

Lifecycle timeline template used for diligence

Pre-expiry: Orange Book patents active; challengers may file Paragraph IV.
Litigation window: claim construction and infringement contentions.
Settlement/approval scheduling: agreed delayed approval dates.
Post-approval: generic launches with potential label carve-outs.
Market stabilization: rebate intensity and formulary switching settle.

(Concrete date mapping requires drug-specific Orange Book patent numbers and expiration events.)

Key Takeaways

DTIs are a compact class dominated by dabigatran (oral), bivalirudin (PCI/ACS), and argatroban (HIT niche).
Generic pressure is strongest for oral prodrugs, where formulation and prodrug behavior patents can still delay or constrain generic label scope.
For injectables, process and stability manufacturing patents often matter as much as composition patents.
Patent leverage in DTI markets is tightly linked to Orange Book-listed formulation and method-of-use claims, and to settlement structures that control launch timing and label carve-outs.
Competitive dynamics with FXa inhibitors compress brand profitability, shifting incentives toward targeted lifecycle strategies and narrowly enforced patents.

FAQs

How do Paragraph IV challenges in direct thrombin inhibitors typically get settled in US district courts?
Do direct thrombin inhibitor formulation patents usually cover dissolution profiles or specific excipient systems?
What launch strategy reduces infringement risk for generic dabigatran etexilate when formulation patents remain?
What quality attributes (impurities, stability) most often delay generic bivalirudin or argatroban manufacturing validation?
How does idarucizumab availability influence formulary decisions and patent enforcement value for dabigatran?

References

(References omitted because no specific drug labels, Orange Book entries, patent numbers, litigation dockets, or FDA status were provided in the prompt.)